Guadecitabine/ICBs, differently from ICBs alone, did not up-regulate the alternative immune checkpoint molecule TIM-3 on T cells, thus preventing this mechanism of tumor escape and exhaustion [60]. This evidence concerns the gene HAVCR2 and neoplasm.